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Abstract
Background: Tetrabenazine (TBZ) selectively depletes central monoamines by reversibly binding
to the type-2 vesicular monoamine transporter. A previous double blind study in Huntington
disease (HD) demonstrated that TBZ effectively suppressed chorea, with a favorable short-term
safety profile (Neurology 2006;66:366-372). The objective of this study was to assess the long-term
safety and effectiveness of TBZ for chorea in HD.
Methods: Subjects who completed the 13-week, double blind protocol were invited to participate
in this open label extension study for up to 80 weeks. Subjects were titrated to the best individual
dose or a maximum of 200 mg/day. Chorea was assessed using the Total Maximal Chorea (TMC)
score from the Unified Huntington Disease Rating Scale.
Results: Of the 75 participants, 45 subjects completed 80 weeks. Three participants terminated
due to adverse events (AEs) including depression, delusions with associated previous suicidal
behavior, and vocal tics. One subject died due to breast cancer. The other 26 subjects chose not
to continue on with each ensuing extension for various reasons. When mild and unrelated AEs
were excluded, the most commonly reported AEs (number of subjects) were sedation/somnolence
(18), depressed mood (17), anxiety (13), insomnia (10), and akathisia (9). Parkinsonism and
dysphagia scores were significantly increased at week 80 compared to baseline. At week 80, chorea
had significantly improved from baseline with a mean reduction in the TMC score of 4.6 (SD 5.5)
units. The mean dosage at week 80 was 63.4 mg (range 12.5-175 mg).
Conclusions: TBZ effectively suppresses HD-related chorea for up to 80 weeks. Patients treated
chronically with TBZ should be monitored for parkinsonism, dysphagia and other side effects
including sleep disturbance, depression, anxiety, and akathisia.
Trial Registration: Clinicaltrials.gov registration number (initial study): NCT00219804
Published: 18 December 2009
BMC Neurology 2009, 9:62 doi:10.1186/1471-2377-9-62
Received: 20 March 2009
Accepted: 18 December 2009
This article is available from: http://www.biomedcentral.com/1471-2377/9/62
© 2009 Frank; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Neurology 2009, 9:62 http://www.biomedcentral.com/1471-2377/9/62
Page 2 of 10
(page number not for citation purposes)
Background
Huntington disease (HD) is a hereditary, progressive neu-
rodegenerative disease clinically characterized by a triad
of chorea, cognitive symptoms and behavioral changes.
Although there is no established treatment to delay the
onset or forestall the progression of HD, symptomatic
treatment of chorea may be beneficial in some individuals
as it may have a favorable impact on motor function,
quality of life and safety [1,2].
Many agents and surgical procedures have been evaluated
in HD for their anti-choreic efficacy including dopamine
depleting agents, dopamine antagonists, benzodi-
azepines, glutamate antagonists, acetylcholinesterase
inhibitors, dopamine agonists, anti-seizure medications,
cannabinoids, lithium, deep brain stimulation, and fetal
cell transplantation [3-5]. A preponderance of the mostly
uncontrolled studies to date supports the use of TBZ in
patients with a variety of hyperkinetic movement disor-
ders, including HD [6-8]. The efficacy of TBZ as an anti-
choreic drug was convincingly demonstrated in a double-
blind, placebo-controlled trial, which demonstrated clear
short-term symptomatic relief of chorea [9]. There is pau-
city of data on the long term use of TBZ, but a few studies
have provided evidence of its long-term efficacy and toler-
ability [7,10].
TBZ is a reversible dopamine depleting agent that is highly
selective for the central vesicular monoamine transporter
type 2 (VMAT2) [11]. TBZ depletes dopamine more selec-
tively over norepinephrine and serotonin by inhibiting
transport into presynaptic vesicles [12,13]. The highest
binding density for TBZ is in the caudate nucleus, puta-
men and nucleus accumbens, areas known to bear the
brunt of pathology in HD [14,15]. VMAT2 binding and
monoamine depletion by TBZ is reversible, lasts hours,
and is not modified by chronic treatment [16,17].
Far too little evidence is available to guide long term
symptomatic treatment in HD. Double-blind and long-
term studies assessing various treatment strategies in HD
are urgently needed [18]. The objective of this open-label
extension study was to assess the long-term safety and effi-
cacy of TBZ in the treatment of chorea in HD.
Methods
Participants
Patients with HD who were ambulatory, had a Total Func-
tional Capacity (TFC) score of greater than 5 and a Total
Maximal Chorea (TMC) score of greater than 9 from the
Unified Huntington Disease Rating Scale (UHDRS), were
initially enrolled in the thirteen-week, double-blind, pla-
cebo-controlled study [9,19]. Subjects were excluded if
they were taking concurrent dopamine depleting drugs, 
dopamine D2 receptor blockers, selective and non-selec-
tive monoamine-oxidase inhibitors, amantadine, levo-
dopa, or dopamine agonists. Participants were permitted
to be on antidepressants, antianxiety agents and other
psychotropic medications at stable doses. Clinically, sub-
jects could not have disabling dysarthria, dysphagia or
depression present at screening or have an unstable or
serious medical or psychiatric illness, untreated depres-
sion or lack of a caregiver.
The subjects completed the double-blind study within
eight weeks of enrollment but were subsequently
excluded if they had suffered from a serious adverse event
(AE) judged to be possibly or probably related to study
drug. There were three possible lengths of enrollment in
the open-label study (Figure 1). The initial protocol con-
sisted of a total of 24 weeks, with 12 weeks of titration and
12 weeks of maintenance. Subjects had the option of
enrolling in an extension of the 24 week study to a total of
48 weeks. At 48 weeks, they had the option of enrolling
for total study duration of 80 weeks. There was a one week
washout following each study phase. Since all participants
had been off TBZ for at least one week following washout
from the double-blind study, baseline for this study was
considered to be the day of enrollment in the open-label
study.
Written informed consent was obtained from all study
participants and accompanying caregivers. In compliance
with the Declaration of Helsinki, this study was approved
by the Research Subjects Review Board at the University of
Rochester as the coordinating site and by the ethics review
boards at all individual sites that enrolled subjects.
TBZ Dosing
TBZ was titrated over a maximum of 12 weeks every 3-7
days to the best individual dose (maximum of 200 mg/
day). All subjects started at 12.5 mg per day and were
titrated upward at the end of each week by 12.5 mg incre-
ments to doses equal to or lower than 125 mg/day, and
then by 25 mg increments for doses higher than 125 mg/
day. If at any time during the titration phase, moderate to
severe, possibly or probably drug-related AEs occurred,
the dose of TBZ was decreased to the patient's previous
well-tolerated dose. Study drug titration (up or down) was
permitted only during the first 11 weeks of the study.
Assessments
Participants were examined at the end of weeks 2, 6, 12,
24 and then every 12 weeks; and had a safety follow-up
visit one week after the end of treatment. Characteristics
of participants and non-participants were compared using
chi-square tests and Kruskal-Wallis tests, as appropriate.BMC Neurology 2009, 9:62 http://www.biomedcentral.com/1471-2377/9/62
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Analysis of Efficacy Endpoints
The primary efficacy endpoint was the TMC score from the
UHDRS at week 80 compared with the baseline TMC
score. TMC score at week 80 was also compared to week
81 (after washout) to determine the degree of re-emergent
chorea. To determine if TBZ may have worsened overall
underlying chorea over time, TMC at week 81 was com-
pared with baseline. T-tests and analysis of covariance
(ANCOVA), adjusted for site and baseline value, were
used to determine significance. Secondary endpoints
included the Clinical Global Impression scale and the
individual sections of the UHDRS.
Analysis of Safety and Tolerability Endpoints
Tolerability was assessed using adverse events, UHDRS
parkinsonism score (total of the following UHDRS motor
items: finger taps, pronation/supination, rigidity, bradyki-
nesia, gait, tandem gait and retropulsion pull test), Barnes
Akathisia Scale (BAS) [20], Unified Parkinson's Disease
Rating Scale (UPDRS) dysphagia and dysarthria scores
[21], and the 17-item Hamilton Depression Measure
(HAM) [22]. Changes from baseline were assessed using t-
tests.
Treatment emergent AEs were designated to be those AEs
that emerged after the start of the open-label study,
excluding those for which subjects had a prior history and
those that had been present during the double-blind
The flow of subjects (including number of subjects) through the trial from enrollment and into each of the extension phases Figure 1
The flow of subjects (including number of subjects) through the trial from enrollment and into each of the 
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study, including those without resolution. Those AEs that
carried over from the double-blind portion of the study
were not considered new events as they have been previ-
ously reported [9]. The time period examined for all AEs
was baseline to last day on study medication, prior to ini-
tiation of washout.
The total number (%) of subjects experiencing at least one
AE was calculated separately for the titration and mainte-
nance periods. McNemar's test was used to compare the
number of subjects experiencing at least one AE during
the titration phase with the number experiencing at least
one AE during the maintenance phase. AEs starting in the
period from the date of baseline visit to week 12 were des-
ignated as having occurred during the titration period. AEs
starting in the period from the first day of week 12 to week
24 were designated as having occurred during the mainte-
nance period. AEs designated as mild and/or not related
to study medication were excluded, and three subjects
with fewer than 13.5 weeks in this study period were
omitted from this analysis.
To determine if 12 additional weeks of exposure to study
medication impacted chorea or HD, efficacy and safety
measures were compared between subjects originally
assigned to placebo and TBZ in the double-blind study
using ANCOVA.
Results
Subject Characteristics
Of the 84 subjects enrolled in the double-blind study, 6
subjects were ineligible to enroll in the open-label study
due to early terminations or serious AEs. Four subjects
decided not to participate due to moving away from the
study site, decision with the caregiver not to enroll due to
lethargy, intensity of protocol, and lost to follow-up.
Although one subject who withdrew from the double-
blind study early due to pre-existing breast cancer was ini-
tially excluded, once medically cleared, she was permitted
to enroll, making a total of 75 subjects who enrolled in
the open-label study (Table 1). Three of the 75 subjects
were excluded from analysis because they terminated at or
prior to the week 12 visit. Forty-two subjects completed
the 80-week extension and washout period (Figure 1).
Excluding subjects who had stopped medication, the
mean daily dosage at week 24 (n = 66) was 74.2 mg (±
40.9, range 12.5 mg-200 mg), week 48 (n = 54) was 71.5
(± 41.5, range 12.5 mg-200 mg) and at week 80 (n = 41)
was 63.4 mg (± 34.2, range 12.5 mg-175 mg). For the 44
subjects with complete dosage data at week 80 (including
three subjects with zero dose), 24 (55%) of participants
were taking either 37.5 mg or 50 mg per day (Figure 2).
Regarding adjustment of dosage for subjects who com-
pleted 80 weeks, 7 (16%) increased their dosage between
weeks 24 and 48, 31 (70%) stayed on the same dose, and
6 (14%) decreased. Between weeks 48 and 80, 6 (14%) of
these subjects increased their dosage, 26 (59%) stayed on
the same dose, and 12 (27%) decreased (including 3 with
week 80 dose = 0 who washed out early).
Tolerability
Twenty subjects terminated from the study. There was one
death due to metastatic breast cancer. Three participants
withdrew due to AEs attributed by the investigators to
TBZ, including vocal tics, depression, and delusions. One
subject terminated because of an elevated bilirubin level
but also reported akathisia, while another subject experi-
enced a significant increase in liver enzymes. One subject
was started on exclusionary medications, and two subjects
were non-compliant with study medications. One subject
was institutionalized, one moved out of the state, and two
were lost to follow-up. The remaining seven terminations
were due to withdrawal of patient consent or by caregiver
or physician request. An additional ten subjects decided
not to continue in ensuing extension phases. Subjects
who completed the study were more likely to be female (p
< 0.01), have higher CAG repeat length (45 vs. 43.5, p <
0.05), and have a lower total functional assessment score
at baseline (18.0 vs. 20.5, p < 0.02). There were no differ-
ences in race, affected parent, history of depression, cho-
rea score, TFC, total motor score, age, years of education
or duration of illness.
There were 12 serious AEs including two falls, two cancer
diagnoses, a single suicide attempt, pneumonia, hip
Table 1: Baseline characteristics (n = 75)
Characteristic
Age (mean ± SD, range) 50.9 ± 11.5, 29.2-77.4
CAGn (mean ± SD, range) 44.5 ± 3.4, 39-54
Women, n (%) 49 (65%)
Caucasian, n (%) 71 (95%)
Affected Parent, n (%)
Mother 33 (44%)
Father 33 (44%)
Unspecified 9 (12%)
Years of Illness duration (mean ± SD, range) 8.5 ± 4.5, 1.9-25.9
History of Depression, n (%) 42 (56%)BMC Neurology 2009, 9:62 http://www.biomedcentral.com/1471-2377/9/62
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replacement (elective) with post-op agitation, agitation,
anxiety, akathisia and one abnormal CA 27-29 titer in a
participant who later died due to metastatic breast cancer.
During the study, 56 subjects reported 170 AEs. Seventeen
subjects reported depressed mood as an AE during this
study with a prior history of depression in 15 of those sub-
jects. All AEs with an incidence of 5% or more are listed in
Table 2. There was no association between any adverse
event and concomitant medications.
When mild or unrelated events were excluded, 39 subjects
reported at least one AE during titration while 20 subjects
reported at least one AE during maintenance (p < 0.001).
Insomnia, somnolence and diarrhea emerged during titra-
tion and subsequently resolved during maintenance. The
number of subjects with somnolence decreased from 36
to 11 (p < 0.0001), insomnia from 14 to 2 (p < 0.003) and
diarrhea from 5 to 1 (p < 0.05) when comparing titration
to maintenance phases.
Safety Measures
Between baseline and week 80, the mean parkinsonism
score increased 2.1 (SD 4.3) UHDRS units (p = 0.002) and
the mean UPDRS dysarthria score increased 0.4 (SD 0.8)
UPDRS units (p < 0.002). There were no significant
changes in the HAM scale scores, UPDRS dysphagia score,
or BAS. Marked or severe akathisia (4 or 5 on the BAS
scale) was experienced by only one participant, who ter-
minated due to elevated bilirubin, rather than akathisia.
Three participants (4%) had mild or moderate akathisia at
baseline. Ten other participants (13.3%) developed mild
or moderate akathisia during the course of the study.
There were 3 participants with isolated elevation of AST,
greater than 3 times the upper limit of normal. Two occur-
rences were at baseline and one at week 24. All abnormal
liver tests returned to normal by week 80 or at the end of
study participation except in one participant with >2
times upper limit of normal AST in isolation. No partici-
pant experienced clinical liver dysfunction, but one partic-
ipant was terminated early due to elevated AST and ALT at
baseline and one subject terminated due to elevated
bilirubin without clear etiology.
Efficacy
When TMC at week 80 was compared to baseline, there
was a reduction in mean TMC score by 4.6 (SD 5.5)
UHDRS units (p < 0.001). At week 81 after washout, cho-
rea re-emerged with a mean TMC score increase of 5.3 (SD
3.2) UHDRS units (p < 0.001 compared to week 80) (Fig-
ure 3). For the 41 participants with complete data, there
Dosage distribution by percent of subjects at weeks 24, 48 and 80 for the 44 subjects who continued to take tetrabenazine  through week 80 Figure 2
Dosage distribution by percent of subjects at weeks 24, 48 and 80 for the 44 subjects who continued to take 
tetrabenazine through week 80.BMC Neurology 2009, 9:62 http://www.biomedcentral.com/1471-2377/9/62
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was no difference in TMC at week 81 (14.9 ± 5.1) when
compared to baseline (15.1 ± 4.3).
At 48 weeks, chorea reduction in the 45 participants who
completed 80 weeks was not significantly different com-
pared to the 11 subjects who completed week 48 but did
not complete the study. After adjusting for study site and
baseline chorea score, there was no association with the
effect of TBZ on chorea related to age, gender, trinucle-
otide repeat length, gender of affected parent, or baseline
clinical global impression of severity. Baseline chorea
score itself was a predictor for greater reduction in chorea
(p = 0.013).
Secondary Efficacy Outcomes
At week 80, there was a significant change in the CGI score
of 0.3 (SD 0.7, p = 0.0054). Of the 45 completers, there
was improvement in 16 (36%) and worsening of 4 (9%)
with the remainder unchanged compared to baseline.
In the 45 participants who completed 80 weeks, there was
no significant change in total motor score, but there were
significant declines in cognitive measures, including ver-
bal fluency, symbol digit and Stroop (reading, color and
Table 2: Treatment emergent AEs reported in >5% of subjects (3 
or more), excluding mild and not related to treatment
Adverse Event # of Subjects
Sedation/Somnolence 18
Depressed Mood 17
Anxiety 13
Insomnia 10
Akathisia 9
Fatigue 7
Agitation 5
Fall 4
Dysphagia 3
Dystonia 3
Mean total maximal chorea score (± SE) by week Figure 3
Mean total maximal chorea score (± SE) by weekBMC Neurology 2009, 9:62 http://www.biomedcentral.com/1471-2377/9/62
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interference) and functional measures as measured by the
functional checklist, independence score and TFC (Table
3).
Placebo vs. TBZ
When the groups initially randomized to placebo and TBZ
were compared, there were no differences in numbers of
subjects with AEs, change in TMC score, change in chorea
after withdrawal, best dosage, or any of the secondary
measures. There was a reduction in the total number of
AEs (p < 0.002) and somnolence (p < 0.01) in mainte-
nance for those subjects initially assigned to TBZ.
Discussion
The double-blind, randomized controlled trial preceding
this study demonstrated that TBZ reduced chorea associ-
ated with HD for up to 12 weeks with the main AEs
including drowsiness and insomnia [9]. In this open label
extension study, TBZ continued to effectively suppress
chorea for up to 80 weeks in HD. TBZ was generally well
tolerated, but treatment emergent AEs included sleep dis-
turbance, depression, anxiety, and akathisia. Akathisia in
particular may be difficult to identify due to confusion
with chorea combined with the lack of insight associated
with HD. During initiation and titration of therapy,
patients may be more prone to sedation, insomnia and
gastrointestinal problems but these tend to improve over
time. Although clinicians should screen for and treat
depression in all patients with HD, those with pre-existing
depression may be at higher risk for developing depres-
sion while taking TBZ [23,24].
Table 3: Baseline scores and changes from baseline in efficacy outcome measures at weeks 24, 48 and 80 [Mean (SD)].
Measure Baseline Week 24 Week 48 Week 80
N = 75 N = 73 N = 57 N = 45
UHDRS Motor Score 47.9 (15.9) -7.4 (9.8) * -5.6 (12.1) * -0.2 (11.0)
Total Chorea 14.9 (3.7) -5.8 (5.0) * -5.6 (5.5) * -4.6 (5.5) *
Gait 1.3 (0.6) -0.1 (0.6) 0.0 (0.7) 0.2 (0.7)
Parkinsonism 14.5 (5.7) -0.5 (2.7) 0.9 (4.1) 2.1 (4.3) *
Barnes Akathisia 0.2 (0.6) 0.1 (1.0) 0.1 (0.9) 0.0 (0.7)
Hamilton 4.1 (3.7) -0.0 (3.8) 0.7 (3.4) 0.4 (3.8)
Functional Checklist 18.1 (4.7) -0.3 (2.5) -1.1 (2.3) * -2.6 (3.3) *
Independence 75.7 (11.5) -2.4 (7.2) * -4.4 (6.0) * -7.0 (8.1) *
Behavioral Score (freq*severity) 6.7 (9.7) 3.4 (14.4) * 2.9 (9.3) * 3.5 (14.4)
Weight (kg) 72.4 (18.8) -1.2 (4.8) * -1.4 (7.4) -1.7 (6.5)
N = 47 N = 45 N = 38 N = 30
Total Functional Capacity 7.6 (2.4) -0.5 (1.5) * -1.1 (1.4) * -2.0 (2.3) *
Verbal 17.2 (10.3) -2.0 (5.6) * -2.0 (5.8) * -3.6 (7.9) *
Symbol Digit 19.3 (11.2) -0.3 (5.5) -1.9 (4.7) * -4.8 (10.3) *
Stroop Color 42.6 (17.3) -4.4 (9.5) * -8.9 (11.4) * -11.0 (14.8) *
Stroop Words 49.8 (20.6) -1.2 (9.3) -7.9 (15.4) * -9.0 (17.4) *
Stroop Interference 23.2 (11.4) -2.7 (7.1) * -4.5 (7.0) * -5.0 (10.4) *
* p < 0.05 (t-test)BMC Neurology 2009, 9:62 http://www.biomedcentral.com/1471-2377/9/62
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In this study, there were no completed suicides, but one
attempt listed as a serious AE and an additional subject
who expressed suicidal ideation. Depression was not
assessed by formal psychiatric criteria, but depressed
mood was screened for using the Hamilton Depression
Scale and item 25 of the UHDRS. During the double-blind
phase of this study, there was a completed suicide in a
subject randomized to the TBZ group, despite scoring
within the normal range on the Hamilton Depression
Scale two weeks prior to the event [9]. Clinicians should
be cautious about the heightened risk of suicide in HD
regardless of depression indexes or use of monoamine
depleters, as overall completed suicide rates are estimated
at 7.3% and up to 25% of patients may attempt suicide at
some point in the illness [25,26]. In patients already diag-
nosed with HD, there may be an increased risk of suicide
particularly when patients enter stage 2 of the disease, a
time when independence diminishes [27].
At the conclusion of this study, the majority of partici-
pants were taking either 50 or 75 mg of TBZ. Notably,
even after subjects had been on TBZ for over one year, dos-
age adjustments continued. In two other open-label, long
term studies of TBZ used for a variety of hyperkinetic con-
ditions including HD, the mean doses after more than two
years were 60.4 and 106.2 mg, respectively [6,7].
Discontinuation of TBZ after 80 weeks of treatment
appears to be safe and is associated with the return of cho-
rea, without significant worsening compared to baseline.
Participants with higher baseline chorea scores experi-
enced a greater reduction in chorea. When TBZ was dis-
continued, no subject developed signs consistent with
neuroleptic withdrawal such as nausea, excessive sweat-
ing, tachycardia or akathisia. We did not identify AEs
related to the withdrawal of TBZ, but other studies have
specifically examined subjects when TBZ is stopped
[9,28]. One subject withdrew due to the development of
"vocal tics". This AE has not been previously reported and
in fact TBZ has been found to be an effective treatment of
tics [29]. It is possible that the "vocal tic" described was
not a TBZ-related AE, but the emergence of tourettism as
a symptom of HD [30].
Participants did not demonstrate a faster than expected
rate of motor or functional decline due to HD. Although
parkinsonism and dysphagia were increased in subjects at
week 80, this finding was likely a result of the natural pro-
gression of disease. Had the parkinsonism been due to a
pharmacological impact of tetrabenazine, we would have
anticipated that the signs would have emerged more
quickly and found on exams throughout the study. TBZ
does not appear to have an effect on cognition or function
after two years of therapy. Participants experienced an
overall improvement on TBZ as demonstrated by the CGI
at week 80, but there was no correlation to support the
association of global improvement with either motor or
chorea change. The UHDRS measures of cognition and
function while taking TBZ declined at a rate consistent
with the natural history of HD. The TFC scale declined 1.6
± 0.4 points over almost two years in those initially
assigned to TBZ, consistent with previously published
measures of TFC [31,32]. Although TBZ is unlikely to
accelerate any aspect of decline in HD, it also does not
appear to have any clinical long-term neuroprotective
role, despite some evidence of potential neuroprotective
effects demonstrated in animal models of HD [33].
The main limitation of this open-label study was the loss
of subjects at each extension phase. The reasons for the
attrition were related to administrative issues and a deci-
sion not to continue rather than any specific AEs. The
majority of patients elected to complete 80 weeks on ther-
apy, and in fact, once the study concluded, some subjects
refused to stop taking TBZ and found other sources of the
study medication prior to its availability on the US mar-
ket. The findings support the clinical impression that cho-
rea suppression in this large cohort of patients can be
valuable to patients and families. The unblinded nature of
this study limits the degree to which we can make conclu-
sions about effectiveness, but the reduction in chorea was
consistent with that seen in the double-blind trial. Further
investigation is needed to determine the effectiveness and
adverse event profile, particularly regarding cognition,
when TBZ is combined with other commonly used medi-
cations.
Conclusions
Chorea, the most striking physical manifestation of HD,
may be disabling and stigmatizing. Frequent or large
amplitude involuntary movements can cause embarrass-
ment or frustration and physical harm due to direct injury
or falls as well as impact quality of life. The impact of sup-
pressing chorea on weight, gait, behavior and functioning
deserves further study, as do the indications for suppress-
ing chorea in the ambulatory high functioning patient
and the more advanced patient in whom chorea may be
injurious. In lieu of discovering therapy that modifies the
global course of the disease, identifying targeted sympto-
matic treatments for HD, such as those for chorea, is a way
to palliate some of the more disabling and stigmatizing
aspects of the disorder. This study confirms efficacy in
long term use and may guide clinicians in dosing and
treatment emergent, long-term adverse effects.
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